Telitacicept
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Telitacicept
- rituximab plus telitacicept
- telitacicept
- Telitacicept
- telitacicept [INN]
- Telitacicept [WHO-DD]
- Telitacicept 160 mg
- Telitacicept 160mg
- Telitacicept 240 mg
- Telitacicept 240mg
- Telitacicept 80 mg
- telitacicept inn
- telitacicept who dd
- Telitacicept-only group
- CAS registry numbers
- 2136630-26-5
- ChEMBL ID
- CHEMBL5095293
- FDA ingredient codes (UNII)
- 1FHM3D7Z49
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- telitacicept
- Type
- Peptide
- Drug name stem
- -cept
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Binding
- Action type
- Binding
- Target
- APRIL
- Gene symbol
- APRIL
- Action
- Binding
- Action type
- Binding
- Target
- BAFF
- Gene symbol
- BAFF
- Condition
- Scleroderma, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000404
- Subject identifier
- D045743
- Condition
- Sjogren's Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000699
- Subject identifier
- D012859
- Condition
- Antiphospholipid Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002689
- Subject identifier
- D016736
- Condition
- Glomerulonephritis, IGA
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004194
- Subject identifier
- D005922
- Condition
- Nephrotic Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004255
- Subject identifier
- D009404
- Condition
- Myasthenia Gravis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004991
- Subject identifier
- D009157
- Condition
- Lupus Nephritis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005761
- Subject identifier
- D008181
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
- Condition identifier
- EFO_0000404
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000685
- Condition identifier
- EFO_0000699
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002689
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004194
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004255
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004991
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005761
- Highest recorded phase
- 2
- Condition identifier
- HP_0001873
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000831
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002869
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005019
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005342
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005377
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005556
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006702
- Condition identifier
- MONDO_0007827
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009688
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0010030
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0015925
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0018013
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019100
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0020108
- Highest recorded phase
- 2
And 1 more, listed on the interactive page.
- Event
- complement factor c3
- Reports
- 1
- Reporting signal score
- 12.5681
- Event
- complement factor c3 increased
- Reports
- 3
- Reporting signal score
- 30.5457
- Event
- hypoalbuminaemia
- Reports
- 5
- Reporting signal score
- 32.8673
- Event
- hypocomplementaemia
- Reports
- 5
- Reporting signal score
- 51.0345
- Event
- proteinuria
- Reports
- 5
- Reporting signal score
- 27.9995
- Event
- systemic lupus erythematosus
- Reports
- 5
- Reporting signal score
- 27.8863
- Event
- treatment failure
- Reports
- 5
- Reporting signal score
- 22.1785
- NCT04905212
- NCT05596708
- NCT05799287
- NCT05078710
- NCT06315530
- NCT05247203
- NCT05306574
- NCT05339217
- NCT05687526
- NCT05929248
- NCT05673993
- NCT05680480
- NCT05737160
- NCT06456580
- NCT06125405
- NCT06375005
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (48)
- A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)
- A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
- A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
- A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)
- A Study of Telitacicept in Lupus Nephritis
- A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
- A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
- A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
- A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
- Chinese Adults With Kidney Disease
- Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
- Effect of Telitacicept on Antibody Titers in Primary APS Patients
- Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
- Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)
- Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
- Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis
- Efficacy and Safety of Telitacicept Combined With Tofacitinib for Refractory Rheumatoid Arthritis
- Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
In development for (8)
- Antiphospholipid syndrome Phase 2
- Diffuse scleroderma Phase 2
- IgA glomerulonephritis Phase 3
- Lupus nephritis Phase 2
- Myasthenia gravis Phase 3
- Nephrotic syndrome Phase 3
- Sjogren syndrome Phase 3
- Systemic lupus erythematosus Phase 3